Controversies in cystic fibrosis - From pediatrician to specialist;Controvérsias na fibrose cística - Do pediatra ao especialista

Jornal de Pediatria

Volumn 78, Issue SUPPL. 2, 2002, Pages

  Ribeiro, Jose Dirceu ^a   Ribeiro, Maria Ângela G de O ^b   Ribeiro, Antonio Fernando ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZTREONAM; BRONCHODILATING AGENT; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MACROLIDE; MEROPENEM; MUCOLYTIC AGENT; NETILMICIN; TOBRAMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BREATHING EXERCISE; CLINICAL FEATURE; CYSTIC FIBROSIS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; GENE THERAPY; HEPATOBILIARY DISEASE; HUMAN; INCIDENCE; LUNG TRANSPLANTATION; MEDICAL LITERATURE; MEDICAL SPECIALIST; MEDLINE; NUTRITIONAL SUPPORT; OXYGEN THERAPY; PANCREAS INSUFFICIENCY; PATHOPHYSIOLOGY; PEDIATRICIAN; PRENATAL DIAGNOSIS; PROGNOSIS; PUBLICATION; REVIEW; TREATMENT OUTCOME;

EID: 0036866333     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/jped.896     Document Type: Review

References (78)

1. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002;15(2):194-222.
2. Doull IJ. Recent advances in Cystic Fibrosis. Arch Dis Child 2001;85(1):62-6.
3. Super M. Milestones in Cystic Fibrosis. Br Med Bull 1992;48(4):713-37.
4. Temkate LP. Cystic fibrosis in the Netherlands. Int. J. Epidemiol 1977;6:23-34.
5. Brunechy, Z. The incidence and genetics of cystic fibrosis. J Med Genet 1972;9:33-37.
6. Dodge JA, Morison S, Lewis PA. Cystic fibrosis in the United Kingdom, 1968-1988: Incidence, population and survival. Pediatr Perinat Epidemiol 1993;7:157-66.
7. Nevanlinna HR. The Finnish population structure, a genetic and genealogical study. Hereditas 1972;71:195-236.
8. Nielsen EL. Cystic Fibrosis: Incidence in Denmark. Acta Paediatr Scand 1972;61:377-9.
9. Raskin S, Phillips JA 3rd, Krishnamani MR, Vnencak-Jones C, Parker RA, Rozov T, et al. DNA analysis of cystic fibrosis in Brazil by direct PCR amplification from Guthrie cards. Am J Med Gen 1993,46:665-9.
10. Tsui LC, Rommens J, Kerem B, Rozmahel R, Zielenski J, Kennedy D, et al. Molecular genetics of cystic fibrosis. Adv Exp Med Biol 1991;290:9-17.
11. Collins FS. Cystic fibrosis: Molecular biology and therapeutic implications. Science 1992;256:774-9.
12. Santis G. Basic molecular genetics. In: Hodson M, Gueddes D. Cystic Fibrosis. London: Chapman & Hall Medical; 1995.p.15-39.
13. Morral N, Bertranpetit J, Estivill X, Nunes V, Casals T, Giménez J, et al. The origin of the major cystic fibrosis mutation (DF508) in European populations. Nat Genet 1994;7:169-75.
14. Martins CSB, Ribeiro AF, Costa, F.F. Frequency of the cystic fibrosis DF508 mutation in a population from São Paulo State, Brazil. Braz J Med Biol Res 1993;26:1037-40.
15. Knowles MR, Stutts MJ, Yankaskas JR, Gatzy JT, Boucher RC Jr. Abnormal respiratory epithelial ion transport in cystic fibrosis. Clin Chest Med 1986;7:285-97.
16. Esterley JR, Oppenheimer EH. Cystic fibrosis of the pancreas: Structural changes in peripheral airways. Thorax 1968;23:270-5.
17. Oppenheimer ER, Esterly JR. Pathology of cystic fibrosis: Review of the literature and comparison with 146 autopsied cases. Perspect Pediatr Pathol 1975;2:241-78.
18. Bedrossian CW, Greenberg SD, Singer DB, Hansen JJ, Rosenberg HS. The lung in cystic fibrosis: A quantitative study including prevalence of pathological finding among different age groups. Hum Pathol 1976;7(2):195-204.
19. Tomashefski JF Jr, Bruce M, Goldberg HI, Dearborn DG. Regional distribution of macroscopic lung disease in cystic fibrosis. Am Rev Respir Dis 1986;133(4):535-40.
20. Mack JF, Moss AJ, Harper WH. The bronchial arteries in cystic fibrosis. Br J Radiol 1965;38:422-9.
21. Rose V. Mechanisms and markers of airway inflammation in cystic fibrosis. Eur Respir J 2002;19(2)333-40.
22. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantification of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999;160:186-91.
23. Park RW, Grand RJ. Gastrointestinal manifestations of cystic fibrosis: A review. Gastroenterology 1981;81:1143-61.
24. Evans AK, Fitzgerald DA, Mckay KO. The impact of meconium ileus on the clinical course of children with cystic fibrosis. Eur Respir J 2001;18(5):784-9.
25. Colombo C, Apostolo MG, Ferrari M. Analysis of risk factors for the development of liver disease associated with Cystic Fibrosis. J Pediatr 1994;124:393-9.
26. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Eng J Med 1993;328:1828-35.
27. Cystic Fibrosis Foundation. Clinical Practice Guidelines for Cystic Fibrosis Committee 1997;1-54.
28. Cystic Fibrosis Foundation. Consensus Conferences. The Diagnosis of Cystic Fibrosis: Consensus Statement 1996;7(1).
29. Storni V, Claustres M, Chinet T, Ravilly S. Diagnostic de la Mucoviscidose. Arch Pédiat 2001;8 Suppl 5:818-32.
30. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959;23:545-9.
31. Denning CR, Huang NN, Cuasay LR, Shwachman H, Tocci P, Warwick WJ, et al. Cooperative study comparing three methods of performing sweat tests to diagnose cystic fibrosis. Pediatrics 1980;66:752-7.
32. Mastella G, Di Cesare G, Borruso A, Menin L, Zanolla L. Reliability of sweat-testing by the Macroduct collection method combined with conductivity analysis in comparison with the classic Gibson and Cooke technique. Acta Paediatr 2000;89(8):933-7.
33. Tsui LC. The cystic fibrosis transmenbrane conductance regulator gene. Am J Respir Crit Care Med 1995;151(3 Pt 2):47-53.
34. Leus J, Van Bieruliet S, Robberecht E. Detection and follow up of exocrine pancreatic insufficiency in Cystic fibrosis: A review. Eur J Pediatr 2000;159:563-8.
35. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for Cystic Fibrosis in the newborn. Lancet 1979;1(8114):472-4.
36. King DN, Heeley AF, Walsh MP, Kusenko JA. Sensitive trypsin assay for dried-blood specimens as a screening procedure for early detection of cystic fibrosis. Lancet 1979;2(8154):1217-9.
37. Merelle ME, Nagelkerke AF, Lees CM, Dezateux C. Newborn screening for cystic fibrosis Cochrane Database Syst Rev 2001;(3):CD001402.
38. Wilcken B, Brow ARD, Urwin R Brown DA. Cystic Fibrosis screening by dried blood spot trypsin assay: Results in 75.000 newborn infants. J Pediatr 1983;102:383-7.
39. Verlinsky Y, Kuliev A. Preimplantation genetic diagnosis. Reprod Med Rev 1999;7:1-14.
40. Massie RJ, Olsen M, Glazner J, Robertson CF, Francis I. Newborn screening for cystic fibrosis in Victoria: 10 Years experience (1989-1998). Med J Aust 2000;172(12):584-7.
41. McCaffery K, Olver RE, Franklin M, Mukhopadhyay S. Systematic review of antistaphilococcal antibiotic therapy in cystic fibrosis. Thorax 1999;54:380-3.
42. Doring G, Conway SP, Heijennan HGM, Hodson ME, Hoiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur Respir J 2000;16(4):749-67.
43. Frederiksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999;28:159-66.
44. Elborn JS, Prescott RJ, Stack BH, Goodchild MC, Bates J, Pantin C, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000;55:355-8.
45. Mukhopadhyay S, Singh M, Carter JI, Ogston S, Franklin M, Olver RE. Nebulized anti-pseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risks. Thorax 1996;51:364-8.
46. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
47. Jones AM, Dodd ME, Webb AK. Burkholderia cepacia: Current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 2001;17(2)295-301.
48. Cohn RC, Rudziensky L. Further observations on amiloridetobramycin synergy in Cystic Fibrosis. Pediatr Pulmonol Suppl 1991; Suppl 6:279.
49. Bush A, Gedds D. Cystic fibrosis in adolescence. European Respiratory Monograph 2002;7(19):225-53.
50. Dezateux C, Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis Cochrane Database Syst Rev 2000;(2):CD001505.
51. Dezateux C, Walters S, Balfour-Lynn I. Inhaled Corticosteroids for Cystic Fibrosis. Cochrane Database Syst Rev 2000;(2):CD 001915.
52. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial. Thorax 2002;57(3):212-6
53. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Sate of the art. Pediatr Pulmonol 2001;31:464-73.
54. Wall MA, LaGesse PC, Istvan JA. The worth of routine spirometry in a Cystic Fibrosis Clinic. Pediatr Pulmonol 1998;25:231-7.
55. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42.
56. Shah PI, Bush A, Canny GJ, Colin AA, Fuchs HJ, Geddes DM, et al. Recombinant human DNase 1 in cystic fibrosis patients with severe pulmonary disease: A short-term, double-blind study followed by six months of open label treatment. Eur Respir J 1995;8:954-58.
57. McCoy C, Hamilton S, Johson C. Effects of 12 week administration of dornasealfa in patients with advanced cystic fibrosis lung disease. Chest 1996;110:889-95.
58. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson C. Short term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83.
59. Borsje P, Jongste JC, Mouton JW, Tiddens HAWM. Aerosol therapy in cystic fibrosis: A survey of 54 CF centers. Pediatr Pulmonol 2000;30:368-76.
60. King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med. 1997;156(1):173-7.
61. Wark PA, McDonald V. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2000;(2):CD001506.
62. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis Cochrane Database Syst Rev. 2002;(1):CD002996.
63. Van Der Schans C; Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database Syst Rev 2000;(2):CD001401.
64. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with Cystic Fibrosis. N Engl J Med 1992;326:1187-91.
65. Bridges ND, Mallory GB Jr, Huddleston CB, Canter CE, Sweet SC, Spray TL. Pediatric lung transplantation at St. Louis Children's Hospital, 1990-1995. Am J Repir Crit Care Med 1997;155:1027-35.
66. Moss RB. Passive immunotherapy for treatment of endobronchitis in Cystic Fibrosis. Infusionsther Transfusionsmed 1993;20 Suppl 1:42-6.
67. Kraisinger M, Hochhaus G, Stecenko A, Bowser E, Hendeles L. Clinical pharmacology of pancreatic enzymes in patients with Cystic Fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994;34:158-66.
68. Lebenthal E, David DK, Holclaw DJ. Enzyme therapy for pancreatic insufficiency. Present status and future needs. Pancreas 1994;9(1)1-12.
69. Cystic Fibrosis Foundation Consensus Conference. Appendix IX, Vol VI, Section I March 1995.
70. Ransey BW, Farrell PM, Pencharg P. Nutritional assessment and management in Cystic Fibrosis: A Consensus Conference Statement. Chest 1998;55:108-16.
71. Geiss SK, Hobbs SA, Hammers LY, Maercklein G et al. Psychosocial factors related to perceived compliance with cystic fibrosis treatment. J Clin Psychol 1992;48:99-103
72. Alton EW, Guedds DM. Gene therapy for Cystic Fibrosis: A clinical prospective. Gene Ther 1995;2:88-95.
73. World Health Organization. Implementation of cystic fibrosis services in developing countries: Memorandum from a joint WHO/ICF(M)A meeting. (World Health Organization/ International Cystic Fibrosis Association) Bulletin of the World Health Organization. 1997;75(1):1-10.
74. Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am 2000;84(3):597-607.
75. Collins CE, Macdonald-Wicks L, Rowe S, O'loughlin EV, Henry RL. Normal growth in cystic fibrosis associated with a specialized center. Arch. Dis. Child 1999;81(3):241-6.
76. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143:1007-17.
77. Macri CN, de Gentile AS, Manterola A, Tomezzoli S, Reis FC, Largo Garcia I, et al. Epidemiology of Cystic Fibrosis in Latin America. Preliminary communication. Pediatr Pulmonol 1991;10:249-53.
78. Camargos PAM, Guimarães MDC, Reis FC. Prognostic aspects of Cystic Fibrosis in Brazil. Ann Trop Pediatr 2000;20(4):287-91.